Briacell Therapeutics Corp experienced a notable uptick in its stock price this week, reflecting investor interest amid recent company developments.
Briacell Therapeutics Corp (BCT.TO) saw its stock rise by 4.54% on Monday, contributing to a weekly gain of 5.19%. The company is currently working on its next-generation personalized immunotherapy candidate for prostate cancer, Bria-PROS+, which has garnered attention following recent announcements.
Advertisement
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeAdvertisement
Market cap
$42.19M
52W high
$20.40
52W low
$3.68
1W change
+5.19%
Beta
1.52
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 294.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+294.5% Upside
Current Price
C$5.07
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
64.1%
Annualized
90-Day Vol
82.4%
Annualized
Trend (90d)
-40.3%
Annualized drift
90d Mean
C$4.39
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.83 | C$3.87 – C$6.03 |
| 60 trading days | C$4.61 | C$3.37 – C$6.30 |
| 90 trading days | C$4.39 | C$2.99 – C$6.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should monitor Briacell's ongoing developments in immunotherapy and the implications of its recent public offering on future growth and market perception.
Briacell's stock remains volatile with a year-to-date decline of 48.37%.
The stock's 52-week range of C$3.68 to C$20.40 indicates significant price fluctuations, highlighting the risks associated with investing in small-cap biotech firms.
Bull case
If Briacell successfully completes the manufacturing of clinical supplies for Bria-PROS+ and its recent public offering proves beneficial, the company could see significant growth. Analysts are optimistic, suggesting a potential target price of C$20.00.
Bear case
Despite the recent gains, Briacell's stock has dropped 48.37% this year. The volatility and the company's negative return on equity may discourage risk-averse investors from getting involved.
Recent Price Action
This week, Briacell Therapeutics Corp's stock closed at C$4.72, marking a 4.54% increase on Monday and contributing to a 5.19% rise over the week. The stock has experienced a decline of 3.80% over the past month, while year-to-date performance shows a significant drop of 48.37%.
Company News and Developments
Advertisement
Briacell recently announced the completion of the manufacturing of clinical supplies for its Bria-PROS+ immunotherapy candidate. This follows a successful $30 million public offering, which has strengthened the company's financial resources for ongoing research and clinical evaluations. Additionally, the company has completed a 300:1 share consolidation to facilitate its listing on a recognized U.S. stock exchange.
Technical Picture
Briacell's stock is currently trading above its 50-day moving average of C$4.69, indicating a slight bullish trend. However, it remains well below its 200-day moving average of C$7.80, suggesting long-term challenges. The stock's beta of 1.52 indicates higher volatility compared to the broader market. The recent trading volume of 5,273 shares is slightly above the 20-day average of 4,820 shares, reflecting increased investor interest.
Insider Activity
No recent insider activity has been reported for Briacell Therapeutics Corp.
Price Action Summary
Briacell Therapeutics Corp closed at C$4.72, reflecting a 1D increase of 4.54%. Investors should remain vigilant about upcoming developments and market reactions as the company progresses with its clinical studies.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
